P
Porton Biologics / 博腾生物
Suzhou CGT CDMO twin of Porton Advanced (plasmids, viral vectors, cell therapy)
About Porton Biologics / 博腾生物
Porton Biologics operates as a subsidiary of Porton Pharma Solutions, a Contract Development and Manufacturing Organization (CDMO) founded in 2005. Porton Biologics itself was established in 2018 and is located in Suzhou Industrial Park, China. The parent company, Porton Pharma Solutions, was co-founded by Chairman and CEO Oliver (Nianfeng) Ju, Hui Chen, and Weiqiang Yang. A significant milestone for Porton Biologics was the closing of a Series A funding round in April 2021, which raised 400 million RMB to be used for the construction and operation of a Phase II commercial production facility.
The company functions as a CDMO platform, providing comprehensive, one-stop drug development and manufacturing services for biologics and conjugates. Its business model is centered on offering end-to-end services that span from early-stage research and preclinical development to clinical trials and commercial production. Porton Biologics serves a global clientele of pharmaceutical companies and biotechs, assisting them in advancing their drug candidates through the clinical pipeline and to the market. Revenue is generated by providing these integrated services for various drug modalities.
The core of Porton Biologics' offering is its integrated service platform for gene and cell therapies, as well as complex biologics. This includes services for plasmids, viral vectors, and various cell therapies. The company's capabilities cover the entire lifecycle, including process development, analytical method development, GMP manufacturing, quality control and release testing, and stability studies. Specifically, their services extend to biologics and conjugates like Antibody-Drug Conjugates (ADCs), Antibody-Oligonucleotide Conjugates (AOCs), and Peptide-Drug Conjugates (PDCs). The platform supports everything from payload-linker process development and manufacturing to conjugation and purification process development, and finally, drug substance and drug product manufacturing, including fill and finish operations.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Aug 2022 | $80M | $320M | HM Capital · State Development & Investment Corporation (SDIC) · CS Capital · Porton Pharma | ↗ |
| SERIES AOther financing | Apr 2021 | $55M | $220M | Momentum Venture Management · HM Capital · State Development & Investment Corporation (SDIC) · GL Ventures | — |
Growth signals
Latest recorded traffic for Porton Biologics / 博腾生物 is 1.2K monthly website visits, up 144.9% over the last three months. Porton Biologics / 博腾生物's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Porton Biologics / 博腾生物 in the Suzhou Shi ecosystem
The Porton Biologics / 博腾生物 office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A13 investors entered at this stage
Momentum Venture Management
HM Capital
State Development & Investment Corporation (SDIC)
GL Ventures
Huatai Zijin Investment- CCChina Merchants Capital
- CSChina Merchants Securities
China Merchants Group
CS Capital
Porton Pharma- GIGortune Investment
- FCFosun Health Capital
- MCMomentum Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Porton Biologics / 博腾生物 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Porton Biologics / 博腾生物’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










